Skip to main content

Table 1 Characteristics of healthy controls (HC) and AS patients

From: Down-regulated miR-495 can target programmed cell death 10 in ankylosing spondylitis

Characteristics AS (N = 150) HC (N = 150)
Gender (Male/Female) Male (N = 114)
Female (N = 36)
Male (N = 114)
Female (N = 36)
Age (years) M: 34.0 ± 12.5
F: 32.5 ± 10.5
M: 35.5 ± 10.5
F: 33.5 ± 8.5
Disease duration (years), mean ± SD 5.5 ± 0.8 0
HLA-B27, mean ± SD (0~147) 161.0 ± 8.5 Normal
ESR (mm/h), mean ± SD (0~15 for Male; 0~20 for Female) 22.5 ± 11.9 Normal
CRP (mg/dL), mean ± SD (1~15) 0.82 ± 0.54 Normal
BASDAI, mean ± SD 4.43 ± 1.35 Normal
BASFI, mean ± SD 36.8 ± 19.6 Normal
mSASSS 13.0 ± 7.0 Normal
Suggestions for immunosuppressant drugs
 Steroids 4% 0
 DMARDs 6% 0
 NSAIDs 100% 0
  1. AS, ankylosing spondylitis; HC, healthy control; SD, Standard Deviation; HLA-B27, Human Leukocyte Antigen (HLA) B27; ESR, Erythrocyte Sedimentation Rate; CRP, C Reactive Protein; BASDAI, Bath Ankylosing Spondylitis Disease Activity; BASFI, Bath Ankylosing Spondylitis Functionality Index; mSASSS, modified Stoke Ankylosing Spondylitis Spine Score; DMARDs, Disease-Modifying Anti-Rheumatic Drugs; NSAIDs, Non-Steroidal Anti-Inflammatory Drugs